Abstract
The use of targeted therapy is growing in the setting of hematopoietic neoplasms. Flow cytometry is a cornerstone of residual disease monitoring post therapy in this group of malignancies. Often, there is overlap between antigens targeted by immunotherapies and gating reagents utilized for population identification by flow cytometry. Such overlap can render a previously excellent gating reagent inadequate for disease detection. Recently, several anti-CD19 T cell-engaging immunotherapeutic agents and an anti-CD22 immunotoxin have been FDA approved for use in B lymphoblastic leukemia (B-LL), with an anti-CD22 T cell-engaging agent in development. In the setting of such targeted therapies, CD19 and CD22 expression may be altered, compromising the use of these reagents for identification of abnormal blasts. We describe herein a strategy for flow cytometric monitoring for residual disease in patients with B-LL post T cell-engaging anti-CD19 and anti-CD22 therapies. © 2018 by John Wiley & Sons, Inc.
References
Jul 30, 2003·Leukemia·S SchwartzE Thiel
Sep 5, 2008·Current Protocols in Cytometry·Brent L Wood
Apr 22, 2009·Cytometry. Part B, Clinical Cytometry·Edmunds Z ReineksHoward J Meyerson
Sep 17, 2011·American Journal of Hematology·Malcolm Acon-LawsCinda Boyer
Dec 18, 2012·Blood·Waleed HasoRimas J Orentas
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Sep 12, 2013·Cytometry. Part B, Clinical Cytometry·Brent WoodUNKNOWN ICSH/ICCS Working Group
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Mar 3, 2015·Pediatric Blood & Cancer·Nirali N ShahAlan S Wayne
Apr 25, 2015·Cytometry. Part B, Clinical Cytometry·Brent L Wood
Apr 29, 2015·Cytometry. Part B, Clinical Cytometry·Emilie CoppinJacques A Nunès
May 23, 2015·Blood·Shannon L MaudeStephan A Grupp
Oct 2, 2015·Therapeutic Advances in Hematology·Sarah K Tasian, Rebecca A Gardner
Apr 7, 2016·Leukemia & Lymphoma·Maria-Elisabeth Goebeler, Ralf Bargou
May 23, 2016·Clinical Pharmacokinetics·Min ZhuSameer Doshi
Oct 16, 2016·Blood Reviews·Xueyan Chen, Brent L Wood
Nov 15, 2016·Current Opinion in Pediatrics·Shannon L Maude
Nov 29, 2016·Best Practice & Research. Clinical Haematology·Saar Gill
Oct 5, 2017·JAMA : the Journal of the American Medical Association·Peter B BachLeonard B Saltz
Oct 5, 2017·Nature Reviews. Clinical Oncology·Vinay Prasad
Nov 21, 2017·Nature Medicine·Terry J FryCrystal L Mackall
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 13, 2018·Journal of Hematology & Oncology·Jian LiQi Zhao
Citations
Jan 26, 2020·Pediatric Blood & Cancer·Haneen ShalabiNirali N Shah
Nov 26, 2020·American Journal of Clinical Pathology·Sindhu Cherian, Lorinda A Soma
Dec 31, 2020·Haematologica·Ekaterina MikhailovaAlexander Popov
Jan 11, 2021·International Journal of Laboratory Hematology·Rodolfo P CorreiaNydia S Bacal
Jan 28, 2021·International Journal of Hematology·Zhiyu LiuCe Shi
Mar 26, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nirali N ShahCrystal L Mackall
Feb 20, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hagop M KantarjianAnjali S Advani
Jun 24, 2021·American Journal of Clinical Pathology·Silvia Saumell TutusausWeina Chen
Aug 5, 2021·British Journal of Haematology·Ekaterina MikhailovaAlexander Popov
Jan 1, 2022·British Journal of Haematology·Alexander PopovLarisa Fechina